Fluoxetine

Indications

For the treatment of canine SEPARATION ANXIETY in conjunction with a behavior modification plan

Dosage and Administration

For use in dogs only. The recommended dose of Reconcile chewable tablets is 1-2 mg/kg administered once daily, in conjunction with a behavior modification plan.

Contraindications

RECONCILE chewable tablets are contraindicated for use in dogs with epilepsy or a history of seizures. RECONCILE chewable tablets should not be given concomitantly with drugs that lower the seizure threshold (e.g., phenothiazines such as acepromazine or chlorpromazine). RECONCILE chewable tablets should not be given in combination with a monoamine oxidase inhibitor (MAOI) [e.g., selegiline hydrochloride (L-deprenyl) or amitraz], or within a minimum of 14 days of discontinuing therapy with an MAOI. RECONCILE chewable tablets are contraindicated in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs. Because fluoxetine and its major metabolite, norfluoxetine, have long half-lives, a 6-week washout interval should be observed following discontinuation of therapy with RECONCILE chew-able tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine.

Warnings

NOT FOR USE IN HUMANS. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN. Additional Information: For complete product information, see attached package insert. For technical assistance or to report an adverse drug experience, call 1-800-874-9764. Additional information available at reconcile.com. Manufactured by Pegasus Laboratories, Inc., Employee-Owned, Pensacola, FL 32514. 07-2021 PRN ​® and Reconcile ® ​ are registered trademarks of Pegasus Laboratories, Inc. CLIENT INFORMATION Your veterinarian has chosen to prescribe RECONCILE chewable tablets along with a simple training plan (a behavioral modification plan) to treat the separation anxiety that affects your dog. Please read this leaflet, which describes the use of RECONCILE chewable tablets. If you have any questions about this information, please consult your veterinarian. Additional information can be found at www.reconcile.com. What are RECONCILE chewable tablets? RECONCILE is a chewable, flavored tablet that you give to your dog once a day to treat separation anxiety. It is administered in conjunction with a simple training plan. RECONCILE chewable tablets are for use in dogs and puppies 6 months of age or older, and 8.8 pounds (4.0 kilograms) or greater. What is Separation Anxiety? Separation anxiety is a disease in which affected dogs may exhibit certain problematic behaviors when left alone. Dogs are social animals, and naturally become bonded to family members in their household. When separated from these people, certain dogs may experience distress and engage in unacceptable behaviors as a result of the anxiety of separation. The more common behaviors associated with separation anxiety include destruction of household items, barking and/or whining, soiling or urinating in the house, heavy drooling and attempting to escape. RECONCILE chewable tablets, when administered in conjunction with a simple training plan that you undertake at home, have been shown to reduce these detrimental behaviors exhibited by your dog. What is a Simple Training Plan (Behavior Modification Plan), and why does my dog need one? Your veterinarian will instruct you on how to incorporate simple training techniques, referred to as “behavior modification.” The combined use of these techniques with RECONCILE chewable tablets has been proven to work faster and better than training alone for the management of separation anxiety. The simple training plan generally consists of several activities, such as: Adapting your dog to your coming and going behavior. Eaching your dog to sit and stay and, over time, to be content in your absence. Resisting the rewarding of inappropriate attention-seeking behaviors. Leaving your dog for short periods, and gradually increasing the time that the dog is left alone. What does my veterinarian need to know about my dog before I give RECONCILE chewable tablets? Your veterinarian is your dog’s healthcare expert and can make the best recommendation for medications for your dog. Key points of your visit may include the following: A thorough physical examination that may include laboratory analysis of blood and/or urine. A discussion of your dog's complete health history, training history and household environment. A discussion of any medications that you are giving now, or have given over the last several months to your dog, including over-the-counter and herbal supplements. How should I give RECONCILE chewable tablets to my dog? RECONCILE is a chewable flavored tablet that is readily consumed by most dogs. If your dog does not readily accept the RECONCILE chewable tablet, it may be offered in food or administered like other tablet medications. Follow your veterinarian’s directions regarding how much medication to administer. If a dose is missed, the next scheduled dose should be given as prescribed. Do not increase or double the dose. If more than the prescribed amount of RECONCILE chewable tablets are given, contact your veterinarian, who is the healthcare expert for your dog. What can I expect from this therapy? Some dogs may show improvement within 1-2 weeks of starting treatment with RECONCILE chewable tablets. Others may take as long as 8 weeks to show improvement. Your veterinarian will monitor the response to RECONCILE chewable tablets and the training plan. If no improvement is noted within 8 weeks, your veterinarian will discuss additional treatment plans for your dog. RECONCILE chewable tablets work by making your dog more receptive to your training program. Although some dogs may appear calmer while on RECONCILE chewable tablets, it does not act as a sedative. What side effects might occur while my dog is taking RECONCILE chewable tablets? As with all medications, side effects may occur. Your veterinarian can best describe these for you and discuss what to do if you observe any unexpected effects or unusual behavior in your dog. The most serious side effect is seizures (convulsions), which in rare and severe cases can result in death. Based on clinical field studies, some animals may appear more calm or lethargic. Additional side effects that may be observed include: decreased appetite, vomiting, shaking or shivering, diarrhea, restlessness, excessive vocalization or whining, aggression, ear infec-tions, disorientation, incoordination, constipation, excessive salivation and weight loss. Since the introduction of RECONCILE, additional side effects reported are anxiety, dilated pupils, panting and confusion. Can other medications be given while my pet is taking RECONCILE chewable tablets? Yes, RECONCILE chewable tablets have been given safely with a wide variety of routinely administered products and medications, including vaccines, antibiotics, anti-inflammatories and products used for the control of fleas, intestinal worms and heartworms. There are a few products and medications that you should not give to your dog before, during or after treatment with RECONCILE chewable tablets because together, they can cause serious side effects. Your veterinarian should be made aware of all products, including over-the-counter and herbal supplements, that you intend to administer to your dog. What else should I know about RECONCILE chewable tablets? RECONCILE chewable tablets are not for use in humans. As with all medications, keep RECONCILE chewable tablets out of reach of children.

Precautions

RECONCILE chewable tablets are not recommended for the treatment of aggression. RECONCILE chewable tablets have not been clinically tested for the treatment of other behavioral dis orders. Studies to determine the effects of RECONCILE chewable tablets in breeding, pregnant, or lactating dogs and in patients less than 6 months of age have not been conducted. Seizures may occur in dogs treated with RECONCILE chewable tablets, even in dogs without a history of epilepsy or seizures (see ADVERSE REACTIONS). Before prescribing RECONCILE chewable tablets, a comprehensive physical examination should be conducted to rule out causes of inappropriate behavior unrelated to separation anxiety. The examination should include a thorough history and assessment of the patient’s household environment and standard practice laboratory tests as appropriate for the patient’s age and health status. Veterinarians should be familiar with the risks and benefits of the treatment of behavioral disorders in dogs before initiating therapy. Inappropriate use of RECONCILE chewable tablets, i.e. in the absence of a diagnosis or without concurrent behavior modification, may expose the animal to un-necessary adverse reactions and may not provide any lasting benefit of therapy. RECONCILE chewable tablets have not been evaluated with drugs that affect the cytochrome P450 enzyme system. RECONCILE chewable tablets should be used with caution when co-administered with any drug that affects the cytochrome P450 enzyme system (for example, ketaconazole). Studies to assess the interaction of RECONCILE chewable tablets with tricyclic antidepressants (TCAs) (for example, amitriptyline and clomipramine) have not been conducted. The minimum washout period to transition dogs from TCAs to RECONCILE chewable tablets has not been evaluated. Published pharmaco-kinetic data demonstrates that TCAs are cleared 4 days following discontinuation. 1, 2

Adverse Reactions

In two North American multi-site field studies, which included a total of 427 dogs, the following adverse reactions were observed: Seizures: In one study, one of 112 dogs in the control group and three of 117 dogs that received RECONCILE chewable tablets experi-enced the serious adverse reaction of seizures. One of the three dogs treated with RECONCILE chewable tablets experienced two seizures 10 days after the end of therapy. Despite escalat-ing phenobarbital doses, the seizures continued and this dog died in status epilepticus approximately six months after the first seizure. Another of the three dogs treated with RECONCILE chewable tablets had experienced one seizure approximately 1½ years prior to study enrollment immediately after receiving head trauma. No additional seizures were reported to have oc-curred until 45 days after concluding treatment with RECONCILE chewable tablets. During the 1½-year period since the second seizure, this dogs seizure activity increased from single seizures to cluster seizures despite increasing doses of phenobarbital and the addition of oral potassium bromide and rectal diazepam. The third dog treated with RECONCILE chewable tablets and the control dog experienced one seizure 24 days and 35 days, respectively, after the start of therapy; no anticonvulsant therapy was initiated and no further seizures were reported in either dog. In the second study, one of 99 dogs treated with RECONCILE chewable tablets and one of 99 dogs treated with the control tablet experienced the serious adverse reaction of seizures 9 and 27 days, respectively, after initiation of therapy. The dog treated with RECONCILE chewable tablets was subsequently diagnosed with vestibular disease and the control dog had a history of recurrent hind leg weakness. In a European multi-site study, 234 dogs were treated with daily doses of fluoxetine chewable tablets ranging from 0.25 mg/kg to 4 mg/kg. One dog treated with a daily dose of 0.4 mg/kg for one month experienced one seizure one week after discontinuing therapy. No anticonvulsant therapy was initiated and no further seizures were reported. Weight loss: Of the dogs in the two North American field studies with body weight measurements throughout the study (n=196 and n=185 in the RECONCILE chewable tablets and control group, respectively), a 5% or greater weight loss (when compared to initial, pre-study body weight) was observed in 58 (29.6%) of dogs treated with RECONCILE chewable tablets and 24 (13.0%) of dogs in the control group. No dogs were withdrawn from clinical studies due to weight loss alone. The following table shows the number of dogs with weight loss, stratified by percent weight loss relative to initial body weight. Table 2: Dogs with Weight Loss (stratified by percent loss relative to initial body weight) Treatment Group 5% to <10% Number (%) 10% to <15% Number (%) 15% Number (%) RECONCILE chewable tablets 44 (22.5%) 13 (6.6%) 1 a (0.5%) Control 20 (10.8%) 4 (2.2%) 0 (0%) a This dog lost 20% of its initial body weight and was the same dog that died in status epilepticus. Other adverse reactions: Additional adverse reactions observed in dogs treated with RECONCILE chewable tablets at a rate of 1% or greater were: Table 3: Adverse Reactions Reported in the North American Field Studies Dose Reduction: Twenty dogs in the RECONCILE chewable tablet group and five dogs in the control group required a reduction in dose due to unacceptable adverse reactions, generally anorexia, vomiting, shaking and depression. Lowering the dose eliminated or reduced the severity of these adverse reactions in the RECONCILE chewable tablet group only. Resumption of the full dose of RECONCILE chewable tablets resulted in a return of the initial adverse reactions in approximately half of the affected dogs. The majority of these adverse reactions were intermittent and mild. However, one dog experienced recurrence of severe adverse reactions, which necessitated withdrawal from the study for that dog. Additionally, two dogs required a second dose reduction of RECONCILE chewable tablets. Effectiveness was maintained in a majority of those dogs in which a dose reduction was necessary. Post Approval Experience (Rev. 2010): The following adverse events are based on post-approval adverse drug experience reporting with RECONCILE chewable tablets. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events are listed in decreasing order of reported frequency: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, and hypersalivation. For a copy of the Safety Data Sheet (SDS) or to report suspected adverse drug events, contact Pegasus Laboratories at 1-800- 874-9764. For additional information about adverse drug expe-rience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/AnimalVeterinary/SafetyHealth. Table 3

Description

RECONCILE is a chewable, flavored tablet that contains fluox-etine hydrochloride. RECONCILE chewable tablets are available in 8, 16, 32, and 64 mg tablet strengths for oral administration to dogs. The active ingredient in RECONCILE chewable tablets is fluoxetine hydrochloride, a selective serotonin reuptake inhibitor (SSRI). The molecular weight of fluoxetine is 345.79. The structural formula is depicted below. molecular structure

Storage

Store at 20-25° C (68-77° F), excursions permitted between 15-30° C (59-86° F). Do not remove desiccant from bottle. Completely close bottle between uses.

Other labels for this ingredient

These labels are also stored for the same active ingredient. They are not identical to the one reprinted above, and each is listed by product and set id rather than merged with it.

• Principal Display Panel, Pegasus Laboratories, Inc.. Set id 16b75f05-7d38-46c1-becf-447f0eca7f2f.
• Principal Display Panel, Pegasus Laboratories, Inc.. Set id 7dd5d1f2-ea05-4885-be93-c0d12c5eeca7.
• Principal Display Panel, Pegasus Laboratories, Inc.. Set id d93a9b64-3404-4ef8-b953-5c2600644052.

FDA adverse event reports

The FDA Center for Veterinary Medicine publishes the adverse event reports it receives through openFDA. The counts below are the reports naming fluoxetine as an active ingredient for each species this label names, as returned on 2026-09-16, coded by the VeDDRA reaction term the reporter chose. Reactions are counted per report, so one report can appear under several terms.

These are counts, not rates. Reporting is voluntary, the number of animals treated is not known, and a widely used product accumulates reports for that reason alone. A report records that an event followed a dose; it does not establish that the product caused it. The counts say nothing about how one product compares with another.